Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model

Molecular Pharmaceutics

Volumn 9, Issue 2, 2012, Pages 261-268

  Vasievich, Elizabeth A ^a   Ramishetti, Srinivas ^a   Zhang, Yuan ^a   Huang, Leaf ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

(R) DOTAP; immunotherapy; melanoma; peptide vaccine

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; GAMMA INTERFERON; TYROSINASE RELATED PROTEIN 2;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; IMMUNOGENICITY; IN VIVO CULTURE; INTERFERON PRODUCTION; LOW DRUG DOSE; LYMPHOCYTE; MELANOMA; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR REGRESSION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; CANCER VACCINES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FATTY ACIDS, MONOUNSATURATED; FEMALE; IMMUNOTHERAPY; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; NEOPLASM TRANSPLANTATION; PARTICLE SIZE; PEPTIDE FRAGMENTS; QUATERNARY AMMONIUM COMPOUNDS; STEREOISOMERISM; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT; VACCINES, SUBUNIT;

EID: 84863121431     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200350n     Document Type: Article

References (27)

1. Flaherty, K. T. Narrative review: BRAF opens the door for therapeutic advances in melanoma Ann. Intern. Med. 2010, 153, 587-91
2. Hersey, P. Immunotherapy of melanoma Asia Pac. J. Clin. Oncol. 2010, 6 (Suppl. 1) S2-8
3. Ko, J. M.; Fisher, D. E. A new era: melanoma genetics and therapeutics J. Pathol. 2011, 223, 241-50
4. Davies, H.; Bignell, G. R.; Cox, C. Mutations of the BRAF gene in human cancer Nature 2002, 417, 949-54 (Pubitemid 34716871)
5. Puzanov, I.; Flaherty, K. T. Targeted molecular therapy in melanoma Semin. Cutaneous Med. Surg. 2010, 29, 196-201
6. Fedorenko, I. V.; Paraiso, K. H.; Smalley, K. S. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma Biochem. Pharmacol. 2011, 82, 201-9
7. Grauer, O. M.; Sutmuller, R. P.; van Maren, W. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model Int. J. Cancer 2008, 122, 1794-802 (Pubitemid 351413426)
8. Jakobisiak, M.; Golab, J. Genetic modification of T cells improves the effectiveness of adoptive tumor immunotherapy Arch. Immunol. Ther. Exp. (Warsz) 2010, 58, 347-54
9. Liu, G.; Khong, H. T.; Wheeler, C. J.; Yu, J. S.; Black, K. L.; Ying, H. Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma J. Immunother. 2003, 26, 301-12 (Pubitemid 36858714)
10. Tang, Y.; Lin, Z.; Ni, B. An altered peptide ligand for naive cytotoxic T lymphocyte epitope of TRP-2(180-188) enhanced immunogenicity Cancer Immunol. Immunother. 2007, 56, 319-29 (Pubitemid 46035902)
11. McWilliams, J. A.; McGurran, S. M.; Dow, S. W.; Slansky, J. E.; Kedl, R. M. A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model J. Immunol. 2006, 177, 155-61 (Pubitemid 43939127)
12. Kou, G.; Shi, S.; Wang, H. Preparation and characterization of recombinant protein ScFv(CD11c)-TRP2 for tumor therapy from inclusion bodies in Escherichia coli Protein Expression Purif. 2007, 52, 131-8 (Pubitemid 46043553)
13. McCormick, A. A.; Corbo, T. A.; Wykoff-Clary, S.; Palmer, K. E.; Pogue, G. P. Chemical conjugate TMV-peptide bivalent fusion vaccines improve cellular immunity and tumor protection Bioconjugate Chem. 2006, 17, 1330-8 (Pubitemid 44455342)
14. Mansour, M.; Pohajdak, B.; Kast, W. M. Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax J. Transl. Med. 2007, 5, 20
15. Jerome, V.; Graser, A.; Muller, R.; Kontermann, R. E.; Konur, A. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant J. Immunother. 2006, 29, 294-305 (Pubitemid 44297297)
16. Triozzi, P. L.; Aldrich, W.; Ponnazhagan, S. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists Vaccine 2010, 28, 7837-43
17. Chen, W.; Yan, W.; Huang, L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid Cancer Immunol. Immunother. 2008, 57, 517-30 (Pubitemid 351170535)
18. Vasievich, E. A.; Chen, W.; Huang, L. Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine. Cancer Immunol. Immunother. 2011
19. Li, S. D.; Chono, S.; Huang, L. Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles J. Controlled Release 2008, 126, 77-84
20. Chono, S.; Li, S. D.; Conwell, C. C.; Huang, L. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor J. Controlled Release 2008, 131, 64-9
21. Byers, A. M.; Kemball, C. C.; Moser, J. M.; Lukacher, A. E. Cutting edge: rapid in vivo CTL activity by polyoma virus-specific effector and memory CD8+ T cells J. Immunol. 2003, 171, 17-21 (Pubitemid 36745267)
22. Rosenberg, S. A.; White, D. E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy J. Immunother. Emphasis Tumor Immunol. 1996, 19, 81-4 (Pubitemid 26127369)
23. Wang, H. Y.; Fu, T.; Wang, G. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells J. Clin. Invest. 2002, 109, 1463-70 (Pubitemid 34596172)
24. Shibagaki, N.; Udey, M. C. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma Eur. J. Immunol. 2003, 33, 850-60 (Pubitemid 36546672)
25. Vasievich, E. A.; Huang, L. The Suppressive Tumor Microenvironment: A Challenge in Cancer Immunotherapy Mol. Pharmaceutics 2011, 8, 635-41
26. Singh, V.; Ji, Q.; Feigenbaum, L.; Leighty, R. M.; Hurwitz, A. A. Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells J. Immunother. 2009, 32, 129-39
27. Calabro, L.; Danielli, R.; Sigalotti, L.; Maio, M. Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications Semin. Oncol. 2010, 37, 460-7